Century Therapeutics, Inc. (NASDAQ: IPSC)

Century Therapeutics Inc is a biotechnology company focused on developing allogeneic pluripotent stem cell derived therapies for autoimmune diseases and cancer. The company uses induced pluripotent stem cells to create off the shelf cell products that can be manufactured at scale and delivered to patients without the need for patient specific cell collection. Its platform includes proprietary gene editing capabilities and an immune evasion technology designed to allow the cells to persist in the host and enable repeat dosing.

Century Therapeutics currently does not generate revenue from product sales as its therapies are still in preclinical or early clinical development. The company receives income through licensing agreements research collaborations and milestone payments from partners such as Fujifilm Cellular Dynamics Bayer HealthCare iCELL Inscripta and Catalent.

Century Therapeutics operates in the highly competitive field of allogeneic cell therapy where it faces large pharmaceutical companies and specialized biotech firms. Key competitors include Bristol Myers Squibb Novartis Roche Gilead Sciences Pfizer and other cell therapy developers such as Fate Therapeutics Allogene Therapeutics and Kyverna Therapeutics. The company differentiates itself through its proprietary induced pluripotent stem cell platform its CRISPR based gene editing capabilities and its Allo Evasion technology that aims to prevent immune rejection and allow repeat dosing.

The company's eventual customers will be patients suffering from autoimmune diseases such as type 1 diabetes lupus and systemic sclerosis as well as patients with B cell malignancies and solid tumors. Healthcare providers hospitals and infusion centers will administer the therapies once they receive regulatory approval.